• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Inovio Pharmaceuticals

Thermo Fisher to manufacture Inovio COVID-19 vaccine candidate

September 9, 2020 By Sean Whooley

Inovio Pharmaceuticals (NSDQ:INO) announced that Thermo Fisher Scientific (NYSE:TMO) will manufacture its COVID-19 vaccine candidate. Plymouth Meeting, Pa.-based Inovio said in a news release yesterday that Thermo Fisher signed a letter of intent to manufacture the INO-4800 COVID-19 vaccine candidate, joining a consortium of third-party manufacturers that aim to produce 100 million doses of Inovio’s vaccine by […]

Filed Under: Business/Financial News, Clinical Trials, Contract Services, Drug-Device Combinations, Featured, Pharmaceuticals Tagged With: coronavirus, COVID-19, Inovio Pharmaceuticals, thermofisherscientific

Inovio to scale up production of smart delivery device for potential COVID-19 vaccine

July 24, 2020 By Sean Whooley

Inovio Pharma

Inovio Pharmaceuticals (NSDQ:INO) announced that it received $71 million from the U.S. Defense Dept. to support its Cellectra 3PSP smart device. Funding from the DoD is set to support large-scale manufacturing for the Cellectra 3PSP and the procurement of Cellectra 2000 devices, which are used to deliver Inovio’s INO-4800 COVID-19 vaccine candidate directly into the skin. […]

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Immunotherapy Tagged With: coronavirus, COVID-19, Inovio Pharmaceuticals, U.S. Defense Dept.

OncoSec, Inovio testing COVID-19 vaccines

April 8, 2020 By Sean Whooley

OncoSec Medical (NSDQ:ONCS) and Inovio Pharmaceuticals (NSDQ:INO) announced that they are testing potential COVID-19 vaccines after the latter received investigational new drug clearance from the FDA. Inovio received an IND nod, while OncoSec’s is pending, but both companies are pursuing a first-in-human Phase 1 clinical trial for their vaccines, according to separate news releases. OncoSec is using […]

Filed Under: Business/Financial News, Clinical Trials, Discovery, Featured, Food & Drug Administration (FDA), Immunotherapy, Pharmaceuticals, Preclinical Trials, Regulatory/Compliance, Research & Development, Respiratory Tagged With: coronavirus, COVID-19, Inovio Pharmaceuticals, OncoSec Medical

Inovio lands $8m Defense grant for intradermal delivery device

June 18, 2019 By Brad Perriello

Inovio Pharma

Inovio Pharmaceuticals (NSDQ:INO) said last week that it won an $8 million grant from a U.S. Defense Dept. agency for the intradermal delivery device it’s developing. The U.S. Defense Threat Reduction Agency agreed to put more than $8.1 million toward the development of Plymouth Meeting, Pa.-based Inovio’s Cellectra 3PSP, a portable, battery-powered intradermal device to deliver […]

Filed Under: Drug-Device Combinations, Featured Tagged With: Inovio Pharmaceuticals

Inovio prices $65m senior notes offering

February 14, 2019 By Sarah Faulkner

Inovio device and logo - updated

Inovio Pharmaceuticals (NSDQ:INO) said today that it priced an offering of $65 million of 6.5% convertible senior notes due 2024. The Plymouth Meeting, Penn.-based company also gave initial purchasers a 13-day option to buy up to an additional $20 million in notes. Inovio expects to reel in roughly $62.7 million in net proceeds from the offering […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Funding Roundup, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Inovio Pharmaceuticals

Inovio touts intradermal delivery of HIV vaccine

October 26, 2018 By Sarah Faulkner

Inovio device and logo - updated

Inovio Pharmaceuticals (NSDQ:INO) reported today that its synthetic HIV vaccine, Pennvax-GP, demonstrated durable antibody and T cell immune responses throughout a Phase I trial. The company found that Pennvax-GP plasmids delivered intradermally with Inovio’s Cellectra device triggered equivalent or superior immune responses in healthy volunteers compared to intramuscular delivery of the plasmids using the same device. […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Inovio Pharmaceuticals

Inovio launches Ph1 study of Hep C vaccine

September 4, 2018 By Sarah Faulkner

Inovio Pharma

Inovio Pharmaceuticals (NSDQ:INO) and its partner, GeneOne Life Science (KSE:011000), said today that the companies have dosed the first patient in a Phase I study designed to test a preventive vaccine against hepatitis C infection. The companies plan to recruit 24 study participants to evaluate Inovio’s GLS-6150 candidate. Participants will include people who have a sustained […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Inovio Pharmaceuticals

Inovio Pharma shares fall on Q1 miss

May 10, 2018 By Fink Densford

Inovio Pharma

Shares in Inovio Pharmaceuticals (NSDQ:INO) have fallen today after the biotech company missed expectations on Wall Street with its first quarter earnings results. The Plymouth Meeting, Penn.-based company posted losses of $32.4 million, or 36¢ per share, on sales of $1.5 million for the three months ended March 31, seeing losses grow 40.1% while sales shrunk […]

Filed Under: Business/Financial News, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: Inovio Pharmaceuticals

Inovio snags $56m award for Lassa fever, MERS vaccines

April 11, 2018 By Sarah Faulkner

Inovio Pharmaceuticals

Inovio Pharmaceuticals (NSDQ:INO) inked a $56 million partnership with the Coalition for Epidemic Preparedness Innovations to develop vaccine candidates against Lassa fever and middle east respiratory syndrome. According to the terms of the deal, CEPI is slated to support Inovio’s preclinical and clinical efforts through to Phase II trials of INO-4500, its Lassa fever vaccine, and […]

Filed Under: Drug-Device Combinations, Featured, Funding Roundup, Pharmaceuticals, Wall Street Beat Tagged With: Inovio Pharmaceuticals

Inovio Pharmaceuticals logs Q4 earnings, sales beat

March 15, 2018 By Sarah Faulkner

Inovio Pharmaceuticals

Inovio Pharmaceuticals (NSDQ:INO) topped sales and earnings estimates on Wall Street yesterday with its fourth quarter and full year results. The Plymouth Meeting, Pa.-based company posted a net loss of -$21.5 million on sales of $8.8 million for the 3 months ended Dec. 31, for bottom-line growth of 17.9% on sales growth of 3.5% compared with […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Immunotherapy, MassDevice Earnings Roundup, Oncology, Pharmaceuticals, Wall Street Beat Tagged With: Inovio Pharmaceuticals

  • Go to page 1
  • Go to page 2
  • Go to Next Page »

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Tweets by DrugDeliveryNow

Footer

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Design & Outsourcing
Medical Tubing + Extrusion

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery News
Advertise with us
About
Contact us
Privacy
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2021 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS